Shin, Incheol
Kang, Keumseok
Kim, Juseong
Sel, Sanghun
Choi, Jeonghoon
Lee, Jae-Wook
Kang, Ho Young
Song, Giltae
Funding for this research was provided by:
National Research Foundation of Korea (2021R1A2C2010775, 2021R1A2C2010775, 2021R1A2C2010775, 2021R1A2C2010775, 2021R1A2C2010775, 2021R1A2C2010775)
Institute of Information & Communications Technology Planning & Evaluation (IITP-2023-00254177, IITP-2023-00254177, IITP-2023-00254177, IITP-2023-00254177, IITP-2023-00254177)
Article History
Received: 24 August 2023
Accepted: 21 November 2023
First Online: 27 November 2023
Declarations
:
: Not applicable.
: Not applicable.
: J.L. and H.Y.K. are full-time employees of Nuclixbio, a biopharmaceutical company that develops cell-penetrating biologics targeting intracellular oncoproteins with proprietary nanocarriers. This commercial affiliation does not alter our adherence to the <i>BMC Bioinformatics</i> policies on sharing data and materials. Other authors declared no competing interests.